Caditam

Product Overview

Caditam is a pharmaceutical formulation containing Tamoxifen (20mg) as its active ingredient, presented in tablet form. Classified as a selective estrogen receptor modulator (SERM), Caditam is primarily indicated for the management of hormone receptor-positive breast cancer. It is also prescribed to reduce the likelihood of breast cancer recurrence in select patients. The medication exerts its therapeutic effect by antagonizing estrogen receptors in breast tissue, thereby inhibiting the proliferation of malignant cells.

Uses

Caditam serves as both adjuvant therapy following surgical or radiation interventions and as primary treatment for metastatic breast cancer. Additionally, it may be utilized for chemoprevention in high-risk populations, including individuals with familial predisposition or specific genetic markers associated with increased breast cancer susceptibility.

How to Use

Administer Caditam tablets orally, with or without food, strictly as prescribed by a healthcare provider. The standard regimen involves once or twice daily dosing for a predetermined treatment period. Tablets should be swallowed intact with adequate water; crushing or chewing is contraindicated. Adherence to prescribed dosing protocols is imperative, and patients should not self-adjust dosage without medical consultation.

Mechanism of Action

The active compound Tamoxifen competitively binds to estrogen receptors on neoplastic cells, creating an estrogen-blockade effect. This action suppresses the growth of hormone-dependent malignancies while potentially inducing apoptosis. Beyond its anti-estrogenic properties in mammary tissue, Tamoxifen demonstrates tissue-specific estrogenic activity, offering ancillary benefits such as bone mineral density preservation in postmenopausal patients.

Dosage and Administration

Therapeutic dosing of Caditam is individualized based on clinical indication and patient-specific factors. Treatment typically commences with lower doses, with gradual titration to achieve optimal therapeutic effect. Duration of therapy varies from several months to multiple years, contingent upon disease stage and biological characteristics. Strict compliance with prescribed regimens is essential for therapeutic efficacy.

Therapeutic Benefits

• First-line therapy for estrogen receptor-positive breast malignancies
• Significantly reduces incidence of cancer recurrence
• Provides prophylactic benefit for high-risk populations
• Generally favorable tolerability profile

Common Adverse Effects

Frequently reported side effects include vasomotor symptoms (hot flashes), genitourinary manifestations (vaginal dryness, menstrual irregularities), gastrointestinal disturbances (nausea), and fatigue. Neuropsychiatric effects such as mood alterations may occur. There exists an elevated thromboembolic risk requiring clinical vigilance. Persistent or severe adverse reactions warrant immediate medical attention.

Important Safety Information

Caditam therapy is associated with increased risks of endometrial carcinoma, thromboembolic events, and other serious complications. Patients with prior thromboembolic disorders, cerebrovascular incidents, or endometrial pathology require careful risk-benefit assessment before initiation. Regular clinical surveillance is mandatory to monitor therapeutic response and detect potential adverse outcomes.

Storage Conditions

Maintain Caditam tablets at controlled room temperature (15-30°C), protected from humidity and direct heat sources. Ensure secure storage away from pediatric and pet access. Discard any medication beyond its printed expiration date.

Disclaimer:

This content is intended solely for educational purposes and represents expert-reviewed medical information. It should not substitute professional medical advice, diagnosis, or treatment. The provided information may not encompass all potential adverse effects, contraindications, or drug interactions. Always consult qualified healthcare personnel regarding medical conditions or therapeutic regimens. This material aims to complement, not replace, the essential physician-patient relationship.